Norethisterone acetate transdermal - Pierre Fabre

Drug Profile

Norethisterone acetate transdermal - Pierre Fabre

Latest Information Update: 15 May 2008

Price : $50

At a glance

  • Originator Amarin Corporation
  • Class Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 01 Apr 2008 Discontinued - Preregistration for Menopausal syndrome in France (Transdermal)
  • 17 Jun 2003 No development reported - Preregistration for Menopausal syndrome in France (Transdermal)
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top